Geography, generalisability, and susceptibility in clinical trials

Jane E. Clougherty; Ellen J. Kinnee; Juan Carlos Cardet; David Mauger; Leonard Bacharier; Avraham Beigelman; Kathryn V. Blake; Michael D. Cabana; Mario Castro; James F. Chmiel; Ronina Covar; Anne Fitzpatrick; Jonathan M. Gaffin; Deborah Gentile; Elliot Israel; Daniel J. Jackson; Monica Kraft; Jerry A. Krishnan; Harsha Vardhan Kumar; Jason E. Lang; Stephen C. Lazarus; Robert F. Lemanske; John Lima; Fernando D. Martinez; Wayne Morgan; James Moy; Ross Myers; Edward T. Naureckas; Victor E. Ortega; Stephen P. Peters; Wanda Phipatanakul; Jacqueline A. Pongracic; Kristie Ross; William J. Sheehan; Lewis J. Smith; Julian Solway; Christine A. Sorkness; Michael E. Wechsler; Sally Wenzel; Steven R. White; Fernando Holguin

doi:10.1016/S2213-2600(21)00046-1

Geography, generalisability, and susceptibility in clinical trials

Jane E. Clougherty
, Ellen J. Kinnee
, Juan Carlos Cardet
, David Mauger
, Leonard Bacharier
, Avraham Beigelman
, Kathryn V. Blake
, Michael D. Cabana
, Mario Castro
, James F. Chmiel
, Ronina Covar
, Anne Fitzpatrick
, Jonathan M. Gaffin
, Deborah Gentile
, Elliot Israel
, Daniel J. Jackson
, Monica Kraft
, Jerry A. Krishnan
, Harsha Vardhan Kumar
, Jason E. Lang

Stephen C. Lazarus, Robert F. Lemanske, John Lima, Fernando D. Martinez, Wayne Morgan, James Moy, Ross Myers, Edward T. Naureckas, Victor E. Ortega, Stephen P. Peters, Wanda Phipatanakul, Jacqueline A. Pongracic, Kristie Ross, William J. Sheehan, Lewis J. Smith, Julian Solway, Christine A. Sorkness, Michael E. Wechsler, Sally Wenzel, Steven R. White, Fernando Holguin

Research output: Contribution to journal › Comment/debate › peer-review

23 Scopus citations

Original language	English (US)
Pages (from-to)	330-332
Number of pages	3
Journal	The Lancet Respiratory Medicine
Volume	9
Issue number	4
DOIs	https://doi.org/10.1016/S2213-2600(21)00046-1
State	Published - Apr 2021

All Science Journal Classification (ASJC) codes

Pulmonary and Respiratory Medicine

Access to Document

10.1016/S2213-2600(21)00046-1

Cite this

Clougherty, J. E., Kinnee, E. J., Cardet, J. C., Mauger, D., Bacharier, L., Beigelman, A., Blake, K. V., Cabana, M. D., Castro, M., Chmiel, J. F., Covar, R., Fitzpatrick, A., Gaffin, J. M., Gentile, D., Israel, E., Jackson, D. J., Kraft, M., Krishnan, J. A., Kumar, H. V., ... Holguin, F. (2021). Geography, generalisability, and susceptibility in clinical trials. The Lancet Respiratory Medicine, 9(4), 330-332. https://doi.org/10.1016/S2213-2600(21)00046-1

@article{7b3b4366c4e842bebb42275aa5f395d1,

title = "Geography, generalisability, and susceptibility in clinical trials",

author = "Clougherty, \{Jane E.\} and Kinnee, \{Ellen J.\} and Cardet, \{Juan Carlos\} and David Mauger and Leonard Bacharier and Avraham Beigelman and Blake, \{Kathryn V.\} and Cabana, \{Michael D.\} and Mario Castro and Chmiel, \{James F.\} and Ronina Covar and Anne Fitzpatrick and Gaffin, \{Jonathan M.\} and Deborah Gentile and Elliot Israel and Jackson, \{Daniel J.\} and Monica Kraft and Krishnan, \{Jerry A.\} and Kumar, \{Harsha Vardhan\} and Lang, \{Jason E.\} and Lazarus, \{Stephen C.\} and Lemanske, \{Robert F.\} and John Lima and Martinez, \{Fernando D.\} and Wayne Morgan and James Moy and Ross Myers and Naureckas, \{Edward T.\} and Ortega, \{Victor E.\} and Peters, \{Stephen P.\} and Wanda Phipatanakul and Pongracic, \{Jacqueline A.\} and Kristie Ross and Sheehan, \{William J.\} and Smith, \{Lewis J.\} and Julian Solway and Sorkness, \{Christine A.\} and Wechsler, \{Michael E.\} and Sally Wenzel and White, \{Steven R.\} and Fernando Holguin",

note = "Funding Information: This work was funded by the NIH National Heart, Lung, and Blood Institute (NHLBI) (1R01HL114536–01: Validating GIS-based methods to address spatial uncertainty in clinical trials, to JEC and FH). The AsthmaNet trials were funded by NIH grants HL098302, HL098096, HL098075, HL098090, HL098177, HL098098, HL098107, HL098112, 098103, and HL098115. All competing interests listed here are during the conduct of the study; competing interests outside of the submitted work are listed in the appendix . JEC, EJK, RC, SPP, LB, KVB, DJJ, FDM, WM, JAP, JS, and SRW report grants from the NIH NHLBI. DM and JFC report grants from the NIH. AB reports grants from Washington University and the NIH. MDC is a member of the United States Preventive Services Task Force (USPSTF); this manuscript does not necessarily represent the views of the USPSTF. JAK reports grants from the NIH, NHBLI, and PCORI. WP reports grants, personal fees, and other support from Genentech/Novartis and Regeneron/Sanofi, other support from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, and Merck. Additionally, full details for competing interests outside of the submitted work for DM, LB, JFC, DJJ, FDM, WM, JAP, JS, and SRW are listed in the appendix . JCC, MC, EI, MK, SCL, RFL, VEO, MEW, SW declare no competing interests related to the submitted work, with full details of other competing interests listed in the appendix . AF, JMG, DG, HVK, JEL, LJS, JL, JM, RM, ETN, KR, WJS, CAS, and FH declare no competing interests. ",

year = "2021",

month = apr,

doi = "10.1016/S2213-2600(21)00046-1",

language = "English (US)",

volume = "9",

pages = "330--332",

journal = "The Lancet Respiratory Medicine",

issn = "2213-2600",

publisher = "Elsevier Ltd",

number = "4",

}

Clougherty, JE, Kinnee, EJ, Cardet, JC, Mauger, D, Bacharier, L, Beigelman, A, Blake, KV, Cabana, MD, Castro, M, Chmiel, JF, Covar, R, Fitzpatrick, A, Gaffin, JM, Gentile, D, Israel, E, Jackson, DJ, Kraft, M, Krishnan, JA, Kumar, HV, Lang, JE, Lazarus, SC, Lemanske, RF, Lima, J, Martinez, FD, Morgan, W, Moy, J, Myers, R, Naureckas, ET, Ortega, VE, Peters, SP, Phipatanakul, W, Pongracic, JA, Ross, K, Sheehan, WJ, Smith, LJ, Solway, J, Sorkness, CA, Wechsler, ME, Wenzel, S, White, SR & Holguin, F 2021, 'Geography, generalisability, and susceptibility in clinical trials', The Lancet Respiratory Medicine, vol. 9, no. 4, pp. 330-332. https://doi.org/10.1016/S2213-2600(21)00046-1

TY - JOUR

T1 - Geography, generalisability, and susceptibility in clinical trials

AU - Clougherty, Jane E.

AU - Kinnee, Ellen J.

AU - Cardet, Juan Carlos

AU - Mauger, David

AU - Bacharier, Leonard

AU - Beigelman, Avraham

AU - Blake, Kathryn V.

AU - Cabana, Michael D.

AU - Castro, Mario

AU - Chmiel, James F.

AU - Covar, Ronina

AU - Fitzpatrick, Anne

AU - Gaffin, Jonathan M.

AU - Gentile, Deborah

AU - Israel, Elliot

AU - Jackson, Daniel J.

AU - Kraft, Monica

AU - Krishnan, Jerry A.

AU - Kumar, Harsha Vardhan

AU - Lang, Jason E.

AU - Lazarus, Stephen C.

AU - Lemanske, Robert F.

AU - Lima, John

AU - Martinez, Fernando D.

AU - Morgan, Wayne

AU - Moy, James

AU - Myers, Ross

AU - Naureckas, Edward T.

AU - Ortega, Victor E.

AU - Peters, Stephen P.

AU - Phipatanakul, Wanda

AU - Pongracic, Jacqueline A.

AU - Ross, Kristie

AU - Sheehan, William J.

AU - Smith, Lewis J.

AU - Solway, Julian

AU - Sorkness, Christine A.

AU - Wechsler, Michael E.

AU - Wenzel, Sally

AU - White, Steven R.

AU - Holguin, Fernando

N1 - Funding Information: This work was funded by the NIH National Heart, Lung, and Blood Institute (NHLBI) (1R01HL114536–01: Validating GIS-based methods to address spatial uncertainty in clinical trials, to JEC and FH). The AsthmaNet trials were funded by NIH grants HL098302, HL098096, HL098075, HL098090, HL098177, HL098098, HL098107, HL098112, 098103, and HL098115. All competing interests listed here are during the conduct of the study; competing interests outside of the submitted work are listed in the appendix . JEC, EJK, RC, SPP, LB, KVB, DJJ, FDM, WM, JAP, JS, and SRW report grants from the NIH NHLBI. DM and JFC report grants from the NIH. AB reports grants from Washington University and the NIH. MDC is a member of the United States Preventive Services Task Force (USPSTF); this manuscript does not necessarily represent the views of the USPSTF. JAK reports grants from the NIH, NHBLI, and PCORI. WP reports grants, personal fees, and other support from Genentech/Novartis and Regeneron/Sanofi, other support from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, and Merck. Additionally, full details for competing interests outside of the submitted work for DM, LB, JFC, DJJ, FDM, WM, JAP, JS, and SRW are listed in the appendix . JCC, MC, EI, MK, SCL, RFL, VEO, MEW, SW declare no competing interests related to the submitted work, with full details of other competing interests listed in the appendix . AF, JMG, DG, HVK, JEL, LJS, JL, JM, RM, ETN, KR, WJS, CAS, and FH declare no competing interests.

PY - 2021/4

Y1 - 2021/4

UR - https://www.scopus.com/pages/publications/85101131601

UR - https://www.scopus.com/pages/publications/85101131601#tab=citedBy

U2 - 10.1016/S2213-2600(21)00046-1

DO - 10.1016/S2213-2600(21)00046-1

M3 - Comment/debate

C2 - 33539731

AN - SCOPUS:85101131601

SN - 2213-2600

VL - 9

SP - 330

EP - 332

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

IS - 4

ER -

Geography, generalisability, and susceptibility in clinical trials

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this